Immune pathways that regulate neutrophil activation and replenishment prevent persistent pneumococcal colonization
Here, we examine immune signaling pathways affecting the duration of primary nasopharyngeal colonization by <i>Streptococcus pneumoniae</i> (<i>Spn</i>), the first step in its pathogenesis. <i>Spn</i> colonization which lasts days to weeks in WT mice was persistent (≥ 6 months) in the absence of IL-17RA-signaling. RNA-seq analysis confirmed the role of IL-17RA signaling in neutrophil-associated pathways. Rather than driving neutrophil specific chemokine expression, IL-17RA-signaling was required to replenish neutrophils in nasal tissue that were otherwise depleted during infection. Enhanced neutrophil trafficking correlated with IL-17RA-dependent expression of endothelial cell adhesion molecules that promote neutrophil trafficking from the circulation into nasal tissue. Persistent colonization was also observed in mice lacking IL-1R-signaling. Recognition of IL-1-family cytokines, however, was not necessary for the expression of IL-17A or neutrophil recruitment. Instead, IL-1R-signaling was associated with the activation of neutrophils in nasal tissue that displayed increased levels of the surface marker CD11b, an important receptor for the complement-opsonized phagocytosis of <i>Spn</i>. Our findings provide insight into the requirement for sustained neutrophil presence and activity to prevent persistent mucosal infection by a leading opportunistic mucosal pathogen.
Authors
- Stephen T. Yeung (ORCID: https://orcid.org/0000-0002-9710-5567)
- Kristen L. Lokken-Toyli (ORCID: https://orcid.org/0000-0002-2058-2015)
- Jeffrey N. Weiser (ORCID: https://orcid.org/0000-0001-7168-8090)
- Teniola Idowu
Institutions
- Mayo Clinic (US)
- Cornell University (US)
- New York University (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-01-15
- DOI
- https://doi.org/10.64898/2026.01.15.699644
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- National Institutes of Health
- School of Medicine, New York University